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ABSTRACT
The interaction between sulbactam and imipenem
was evaluated with four clinical isolates of Acine-
tobacter baumannii, including two isolates resistant
to imipenem, one of which produced IMP-1
metallo-b-lactamase. Two isolates (one of which
was imipenem-resistant) were sulbactam-resist-
ant by undefined mechanisms. MICs were deter-
mined by standard broth microdilution methods.
Time-kill assays with imipenem and sulbactam,
alone or in combination at 0.5 · MIC and
1 · MIC, showed a synergic effect in all four
isolates of A. baumannii after incubation for 0, 4,
8 and > 24 h at 35C.
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Acinetobacter baumannii has emerged worldwide
as an important nosocomial pathogen that is
difficult to treat because of its multiple antibiotic
resistance [1]. Most nosocomial isolates of
A. baumannii are now resistant to a wide variety
of antibiotics, with carbapenems being the main
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remaining therapeutic choice [2,3]. In the hospital
setting, overuse of imipenem has been associated
with several outbreaks caused by carbapenem-
resistant strains, which leaves polymyxin, and
perhaps sulbactam, as the only antibiotics with
in-vitro activity against these organisms [2,4].
Therapy in such cases is a serious challenge, and
consequently, the activity of sulbactam against
the genus Acinetobacter is receiving renewed
attention [5]. However, resistance to sulbactam
has already been noted in imipenem-resistant
strains of A. baumannii, leaving polymyxin as the
only treatment alternative [6,7]. Levin et al. [8]
reported the outcomes of 60 nosocomial infec-
tions, including bacteraemia, caused by A. bau-
mannii and Pseudomonas aeruginosa isolates that
were resistant to all commercially available anti-
microbial agents. These infections were treated
with colistin, although colistin can have import-
ant adverse effects such as nephrotoxicity or
neurotoxicity. Other therapeutic options are
required urgently.
A few reports have described the interactions
between carbapenems and sulbactam in A. bau-
mannii. Ko et al. [9] reported that meropenem
combined with sulbactam exhibited more potent
antimicrobial activity against multiresistant
A. baumannii than did meropenem or sulbactam
alone. Wolff et al. [10] found that imipenem and
sulbactam did not provide true bactericidal effects
against A. baumannii in a mouse pneumonia
model, but the interactions between imipenem
and sulbactam against A. baumannii remained
unclear.
The present study investigated the in-vitro
antibacterial activity of imipenem combined with
sulbactam against four clinical isolates of A. bau-
mannii selected on the basis of their resistance
phenotypes. Strain YMC01 ⁄ 7 ⁄R234 produced
PER-1 extended-spectrum b-lactamase, while
YMC01 ⁄ 7 ⁄P40 produced IMP-1 metallo-b-lacta-
mase, as confirmed by PCR-based detection of the
blaPER-1 and blaIMP-1 genes, respectively [11,12].
Strains YMC01 ⁄ 7 ⁄R520 and YMC01 ⁄ 7 ⁄R300 were
susceptible to imipenem. Strains YMC01 ⁄ 7 ⁄R234
and YMC01 ⁄ 7 ⁄R520 were resistant to sulbactam
by undefined mechanisms. The strains were not
clonally related.
The antibiotics used for the tests were imipe-
nem (MSD, Seoul, Korea) and sulbactam (Pfizer,
Seoul, Korea). MICs were determined with the
standard broth microdilution method [13], with
an inoculum of 5 · 105 CFU ⁄mL in Mueller–
Hinton broth, and results were read after incuba-
tion for 20 h at 35C. The antibiotics were diluted
in two-fold steps in Mueller–Hinton broth to
give concentrations of 0.008–128 mg ⁄L. Time-kill
assays were performed with 1.5 · 106 CFU ⁄mL in
trypticase soy broth and antibiotic concentrations
of 0.5· and 1· MIC. Imipenem and sulbactam
were tested alone and in combination, with
incubation for 0, 4, 8 and 24 h at 35C. Following
incubation, aliquots (0.1 mL) were diluted ten-
fold in sterile saline and plated on to trypticase
soy agar plates; colonies were counted on plates
yielding 10–100 colonies after incubation for 24 h
at 35C. All time-kill experiments were performed
in triplicate. Synergy and additivity ⁄ indifference
were defined, respectively, as a ‡ 2 log10 CFU ⁄mL
decrease, and a < 2 log10 CFU ⁄mL change in the
viable count after incubation with the combina-
tion for 24 h, compared with the viable count in
the presence of the more active of the two
antibiotics used.
MICs of imipenem and sulbactam for the four
A. baumannii strains are listed in Table 1. The
MICs of imipenem ranged from 0.12 to 16 mg ⁄L,
and those for sulbactam from 1 to 64 mg ⁄L. Fig. 1
shows the killing activities of imipenem and
sulbactam, alone and in combination, expressed
as log10 CFU ⁄mL changes in the number of
surviving bacteria after incubation for 0, 4, 8 and
24 h. The combination of imipenem and sulbac-
tam produced a synergic effect against all four
A. baumannii strains.
Sulbactam is a b-lactamase inhibitor with low
antibacterial activity against most microorgan-
isms except Neisseria gonorrhoeae, Neisseria menin-
gitidis, Burkholderia cepacia and Acinetobacter spp.
[14,15]. However, in addition to anti-b-lactamase
Table 1. MICs of imipenem and sulbactam for Acineto-
bacter baumannii and the killing activity of sulbactam
combined with imipenem against A. baumannii
Strain
MIC (mg ⁄L)
Killing activitya of sulbactam
combined with imipenem
Imipenem Sulbactam 0.5· MIC 1· MIC
YMC01 ⁄ 7 ⁄R234 16 64 ) 6.63 ± 0.08 S ) 4.62 ± 0.06 S
YMC01 ⁄ 7 ⁄P40 16 8 ) 5.82 ± 0.11 S ) 6.61 ± 0.02 S
YMC01 ⁄ 7 ⁄R520 1 64 ) 5.24 ± 0.10 S ) 1.24 ± 0.06 A
YMC01 ⁄ 7 ⁄R300 0.12 1 ) 4.74 ± 0.05 S ) 3.12 ± 0.06 S
aExpressed as a change in log10 CFU ⁄mL at 24 h produced by the combination,
compared with that produced by the most active agent used alone.
S, synergic; A, additive ⁄ indifferent.
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activity, sulbactam can bind to bacterial penicil-
lin-binding protein 2 (PBP2). Since the activity of
most penicillins and cephalosporins results from
binding to PBP1 and PBP3, the combination of
sulbactam with a penicillin or a cephalosporin
may result in a synergic effect [14].
Imipenem was the first commercially available
carbapenem and has an excellent spectrum of
antimicrobial activity. It rapidly penetrates the
outer-membrane of Gram-negative bacteria, and
has excellent stability to class C and A serine
b-lactamases, including extended-spectrum b-lac-
tamases [16]. Imipenem and meropenem possess
important activity against most Gram-negative
bacteria because of their high affinity for PBPs
such as PBP2 and ⁄ or PBP3.
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Fig. 1. Bactericidal activity of imipenem and sulbactam alone or combined against four strains of Acinetobacter baumannii:
diamonds, imipenem; squares, sulbactam; triangles, imipenem + sulbactam. (a) Strain YMC01 ⁄ 7 ⁄R234 at 1· MIC. (b)
Strain YMC01 ⁄ 7 ⁄R234 at 0.5x MIC. (c) Strain YMC01 ⁄ 7 ⁄P40 at 1· MIC. (d) Strain YMC01 ⁄ 7 ⁄P40 at 0.5x MIC. (e) Strain
YMC01 ⁄ 7 ⁄R520 at 1· MIC. (f) Strain YMC01 ⁄ 7 ⁄R520 at 0.5x MIC. (g) Strain YMC01 ⁄ 7 ⁄R300 at 1· MIC. (h) Strain
YMC01 ⁄ 7 ⁄R300 at 0.5x MIC.
1100 Clinical Microbiology and Infection, Volume 10 Number 12, December 2004
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10, 1089–1104
In the present study, sulbactam and imipenem
were found to act synergically against four strains
of A. baumannii, including two imipenem-resistant
A. baumannii strains. The affinity of sulbactam for
PBP2 and of imipenem for PBP3 may be the cause
of such synergic interactions. However, imipenem
has good affinity for the PBP2 of Gram-negative
bacteria, and it has been reported that reduced
expression of PBP2 is related to reduced suscep-
tibility or resistance to carbapenems [17]. There-
fore, it seems possible that another mechanism
might be involved in the synergic interactions
observed in the present study. Further studies
with a larger number of strains are required to
confirm these observations. In addition, the
expression of PBPs was not investigated, and
thus it was not possible to evaluate the precise
mechanism(s) of synergy. It will also be necessary
to determine the mechanisms responsible for
resistance in the strains tested.
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